Misonix Inc(MSON) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

Misonix, Inc., together with its subsidiaries, designs, develops, manufactures, and markets minimally invasive surgical ultrasonic medical devices in the United States and internationally. The company's products include BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting and sculpting of bone while sparing soft tissue; SonaStar, a surgical aspirator that is used to emulsify and remove soft and hard tumors primarily in the neuro and general surgery field; and SonicOne, an ultrasonic cleansing and debridement system, which provides tissue specific debridement and cleansing of wounds and burns for the removal of devitalized tissue and fibrin deposits while sparing viable cells. Its products are used in various clinical specialties, such as neurosurgery, orthopedic surgery, general surgery, plastic surgery, wound care, and maxillo-facial surgical applications. The company sells its products through sales representatives and distributors. Misonix, Inc. was founded in 1959 and is based in Farmingdale, New York.

Current Price

$18.25

RSI

34.695

Beta:

1.452289

February 04, 2021
43.9M
-1.5M

-12.244 %
24.419 %
75.150 %
-75.468 %

$61,552,777
$40,253,921
$36,679,826
$27,269,963
$23,113,194
$22,204,578
52.911 %
9.744 %
34.506 %
17.984 %
4.092 %

$-21,916,952
$-7,358,250
$-2,195,789
$-2,703,987
$-1,745,497
$2,519,424
-66.427 %
-70.159 %
23.144 %
-35.447 %
-244.338 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.